JUPITER Trial

Jump to: navigation, search

Low Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low LDL
High LDL

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Prognosis and Complications

Diagnosis

Laboratory Findings

Treatment

Medical Therapy

Landmark Trials

Future or Investigational Therapies

Case Studies

Case #1

JUPITER Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of JUPITER Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on JUPITER Trial

CDC on JUPITER Trial

JUPITER Trial in the news

Blogs on JUPITER Trial

Directions to Hospitals Treating Low density lipoprotein

Risk calculators and risk factors for JUPITER Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for JUPITER.

Overview

This most recent trial randomly assigned 17,802 healthy subjects with LDL < 130 mg/dL and high-sensitivity CRP > 2 g/L to Rosuvastatin 20 mg daily or placebo. A significant reduction in the composite and individual components of the primary end-point of myocardial infarction, stroke, arterial revascularization hospitalization for unstable angina or death from cardiovascular causes and all-cause mortality was noted and trial was stopped earlier at 1.9 years (maximum of 5 years)[1].

References

  1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ; et al. (2008). "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein". N Engl J Med. 359 (21): 2195–207. doi:10.1056/NEJMoa0807646. PMID 18997196. Review in: Evid Based Med. 2009 Apr;14(2):48 Review in: Ann Intern Med. 2009 Jan 20;150(2):JC1-4

Linked-in.jpg